Why the study?
Does intradermal administration of fractional doses of inactivated poliovirus vaccine provide adequate immunogenicity and operational feasibility compared to full intramuscular doses?
Does intradermal administration of fractional doses of inactivated poliovirus vaccine provide adequate immunogenicity and operational feasibility compared to full intramuscular doses?
Intradermal administration of fractional doses of inactivated poliovirus vaccine is an immunogenic and operationally feasible dose-sparing strategy to stretch global vaccine supply.
Answers are grounded in this paper and cite their sources.
Supports fractional dosing as a viable strategy to stretch global vaccine supply; leaves open the need for long-.
A fractional dose of inactivated poliovirus vaccine (fIPV) administered by the intradermal route delivers one fifth of the full vaccine dose administered by the intramuscular route and offers a potential dose-sparing strategy to stretch the limited global IPV supply while further improving population immunity. Multiple studies have assessed immunogenicity of intradermal fIPV compared with the full intramuscular dose and demonstrated encouraging results. Novel intradermal devices, including intradermal adapters and disposable-syringe jet injectors, have also been developed and evaluated as alternatives to traditional Bacillus Calmette-Guérin needles and syringes for the administration of fIPV. Initial experience in India, Pakistan, and Sri Lanka suggests that it is operationally feasible to implement fIPV vaccination on a large scale. Given the available scientific data and operational feasibility shown in early-adopter countries, countries are encouraged to consider introducing a fIPV strategy into their routine immunization and supplementary immunization activities.
No takes yet. Share an insight, caveat, or question.
Okayasu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: